The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Wyeth-Ayerst Laboratories
Approval Status: Approved January 1998
Treatment for: Hormone replacement therapy
General Information
Prempro has been cleared for marketing with a new, increased progestin dose. The new dose of Prempro (conjugated estrogens/medroxyprogesterone acetate tablets) contains 0.625 mg Premarin (conjugated estrogens) and 5 mg medroxyprogesterone acetate. The previously approved dose contains 0.625 mg Premarin and 2.5 mg medroxyprogesterone acetate. The drug is approved for use as a combination estrogen and progestin hormone replacement therapy.
Side Effects
Common side effects may include nausea, breast tenderness, headaches, and abdominal pain.
